Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Case Comprehensive Cancer Center
Modality
protein_peptide
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03591614CT.gov Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Monoclonal Gammopathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dickkopf-Related Protein 1 (this asset) | Case Comprehensive Cancer Center | Early P1 | C · 39 |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Liraglutide | University of Miami | P4 | BB |
| Adriamycin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | BB |
| (+)-Vincristine | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | B |
| Daratumumab | Hellenic Society of Hematology | P2 | B |
| Pomalidomide | Hellenic Society of Hematology | P1/2 | CC |
| Belantamab Mafodotin | Hellenic Society of Hematology | P1/2 | CC |
| Lenalidomide | Hellenic Society of Hematology | P1/2 | CC |
+3 more in the Monoclonal Gammopathy cohort
Other indications for Dickkopf-Related Protein 1
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Smoldering Plasma Cell Myeloma | — | Early P1 | C · 39 |
| Plasma Cell Myeloma | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dickkopf-Related Protein 1 in Monoclonal Gammopathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dickkopf-related-protein-1-monoclonal-gammopathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →